Using Cancer Proteomics Data to Identify Gene Candidates for Therapeutic Targeting



May 9, 2023

  • Share
  • Oncotarget published this research perspective on May 4, 2023 in Volume 14, entitled, “Using cancer proteomics data to identify gene candidates for therapeutic targeting" by researchers from the Center for Drug Discovery, Baylor College of Medicine, Houston, TX; Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX; Dan L. Duncan Comprehensive Cancer Center Division of Biostatistics, Baylor College of Medicine, Houston, TX; Cancer and Cell Biology Program, Baylor College of Medicine, Houston, TX; O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL; Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL; Genomic Diagnostics and Bioinformatics, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL; The Informatics Institute, University of Alabama at Birmingham, Birmingham, AL; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX; Department of Medicine, Baylor College of Medicine, Houston, TX. DOI - Correspondence to - Chad J. Creighton - Abstract Gene-level associations obtained from mass-spectrometry-based cancer proteomics datasets represent a resource for identifying gene candidates for functional studies. When recently surveying proteomic correlates of tumor grade across multiple cancer types, we identified specific protein kinases having a functional impact on uterine endometrial cancer cells. This previously published study provides just one template for utilizing public molecular datasets to discover potential novel therapeutic targets and approaches for cancer patients. Proteomic profiling data combined with corresponding multi-omics data on human tumors and cell lines can be analyzed in various ways to prioritize genes of interest for interrogating biology. Across hundreds of cancer cell lines, CRISPR loss of function and drug sensitivity scoring can be readily integrated with protein data to predict any gene’s functional impact before bench experiments are carried out. Public data portals make cancer proteomics data more accessible to the research community. Drug discovery platforms can screen hundreds of millions of small molecule inhibitors for those that target a gene or pathway of interest. Here, we discuss some of the available public genomic and proteomic resources while considering approaches to how these could be leveraged for molecular biology insights or drug discovery. We also demonstrate the inhibitory effect of BAY1217389, a TTK inhibitor recently tested in a Phase I clinical trial for the treatment of solid tumors, on uterine cancer cell line viability. Sign up for free Altmetric alerts about this article - Subscribe for free publication alerts from Oncotarget - Keywords - proteomics, proteogenomics, multi-omics, cancer, TTK protein kinase About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit and connect with us: SoundCloud - Facebook - Twitter - Instagram - YouTube - LinkedIn - Pinterest - Reddit - Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

    Analytical TechniquesCancer ResearchCell ScienceMolecular Biology

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.